A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus - Ikeda, S; Takano, Y; Cynshi, O (Diabetes Obes Metab, 2015)
et al.